Efficacy of Tirzepatide in People with Young-Onset T2D in the SURPASS Program
In this medfyle
Tirzepatide improves HbA1c, weight, and cardiometabolic markers in both young-onset and later-onset type 2 diabetes.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This content is intended for an international audience of non-UK healthcare professionals. The content is made available through a licensing agreement between Infomedica and the American Diabetes Association (ADA).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the ADA.
©2023 Infomedica-Medfyle. All rights reserved
